Literature DB >> 24792497

Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM).

S M Restrepo-Gualteros1, C E Rodriguez-Martinez2, L E Jaramillo-Barberi3, A F Lopez-Cadena4, G Nino5.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24792497      PMCID： PMC4214905          DOI： 10.1016/j.aller.2013.10.004

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN： 0301-0546            Impact factor:   1.667


× No keyword cloud information.
  10 in total

1.  Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy.

Authors:  Teng Moua; Eric J Olson; Hope C St Jean; Jay H Ryu
Journal:  Am J Respir Crit Care Med       Date:  2012-08-15       Impact factor: 21.405

2.  Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.

Authors:  M van Slegtenhorst; M Nellist; B Nagelkerken; J Cheadle; R Snell; A van den Ouweland; A Reuser; J Sampson; D Halley; P van der Sluijs
Journal:  Hum Mol Genet       Date:  1998-06       Impact factor: 6.150

3.  European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.

Authors:  S R Johnson; J F Cordier; R Lazor; V Cottin; U Costabel; S Harari; M Reynaud-Gaubert; A Boehler; M Brauner; H Popper; F Bonetti; C Kingswood
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

4.  Milestones in lymphangioleiomyomatosis research.

Authors:  V Cottin; F Archer; C Leroux; J-F Mornex; J-F Cordier
Journal:  Eur Respir Rev       Date:  2011-03

Review 5.  A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.

Authors:  Daniel F Dilling; Emily R Gilbert; Maria M Picken; Jonathan M Eby; Robert B Love; I Caroline Le Poole
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01       Impact factor: 6.914

Review 6.  Current management of lymphangioleiomyomatosis.

Authors:  Camille Taillé; Raphaël Borie; Bruno Crestani
Journal:  Curr Opin Pulm Med       Date:  2011-09       Impact factor: 3.155

Review 7.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

8.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Authors:  Francis X McCormack; Yoshikazu Inoue; Joel Moss; Lianne G Singer; Charlie Strange; Koh Nakata; Alan F Barker; Jeffrey T Chapman; Mark L Brantly; James M Stocks; Kevin K Brown; Joseph P Lynch; Hilary J Goldberg; Lisa R Young; Brent W Kinder; Gregory P Downey; Eugene J Sullivan; Thomas V Colby; Roy T McKay; Marsha M Cohen; Leslie Korbee; Angelo M Taveira-DaSilva; Hye-Seung Lee; Jeffrey P Krischer; Bruce C Trapnell
Journal:  N Engl J Med       Date:  2011-03-16       Impact factor: 91.245

Review 9.  Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.

Authors:  Stephen C Juvet; Francis X McCormack; David J Kwiatkowski; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-10       Impact factor: 6.914

Review 10.  Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis.

Authors:  Connie G Glasgow; Souheil El-Chemaly; Joel Moss
Journal:  Eur Respir Rev       Date:  2012-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.